Development Of An Interleukin-11 Signalling Antagonist
Funder
National Health and Medical Research Council
Funding Amount
$625,830.00
Summary
Interleukin (IL)-11 is a soluble signalling molecule that is associated with many types of cancer. We have recently discovered that IL-11 signalling is a novel and tractable therapeutic target for the treatment of colon cancer. The aims of this proposal are to understand the structural details of IL-11 signalling. We will use this information to develop new and improved therapeutics for colon cancer.